The Multiple Works in Both Directions
A facility sized as a multiple of recurring revenue is recalculated regularly. Everyone models what that does when revenue grows. The same formula runs in reverse.
The appeal of recurring revenue debt is that availability tracks the business. Add MRR and the facility grows with it, with no second underwriting and no new negotiation. That is a genuine feature, and it is how these facilities are sold.
It is also symmetrical, and the symmetry is rarely modelled by the borrower.
Five quarters up, one quarter down
Take an illustrative case. A vertical software company selling to field-service businesses runs $500,000 of MRR and grows about 4 percent a month. Its facility is sized at an illustrative five times MRR, recalculated monthly against the most recent month.
Fifteen months in, MRR is $866,000 and availability is $4.33 million. The company draws to $3.8 million to fund a sales hiring plan, leaving a little over $500,000 of headroom. Every number in that decision is accurate on the day it is made.
Then a quarter goes wrong. A large customer leaves at renewal, two others downgrade seats, and new logos slow. Over three months MRR falls 21 percent, from $866,000 to $685,000.
Nothing about that is unusual. It is a bad quarter in a business that remains perfectly viable.
What the recalculation does
Availability follows MRR down: $3.68 million, then $3.46 million, then $3.42 million.
The drawn balance is still $3.8 million. So the company is over its limit by $120,000, then $340,000, then $376,000, and in most agreements a borrowing base deficiency is repayable within days of the certificate that reports it.
The company now has to find cash in the quarter it least has it, which is the quarter it borrowed to get through.
The convention decides the outcome
Here is the part worth negotiating before signing. Had the same facility been tested against a trailing six-month average of MRR rather than the current month, availability would have been $3.95 million, $3.91 million and $3.84 million through the same decline.
Same business, same customers leaving, same month. Headroom of $150,000, $110,000 and $40,000 instead of a demand for $376,000.
That is not a loophole. It is a different and defensible way to measure the same collateral, and it costs the borrower something real on the way up: an averaged test lags growth, so a company adding MRR quickly gets access later than a current-month test would give it.
Which makes it a genuine trade rather than a free win. A company that expects to sit near its limit should take the smoothing. A company that will stay well inside its availability and wants capacity to track a fast ramp may rationally prefer the current-month test.
The error is not choosing. Most borrowers never see the choice, because the averaging convention sits in the definitions rather than in the term sheet.
Four terms that decide how hard a reset lands
The lookback. Current month, trailing three months, or trailing six. This single definition moved the outcome above by half a million dollars.
A floor or step-down. Some facilities cap how far availability can fall in a single period, or step it down over 90 days rather than at once. That converts a cliff into a schedule the business can plan against.
The cure window. Deficiencies are often repayable in three to ten business days. Twenty or thirty is negotiable, and so is the right to cure with equity proceeds rather than only cash on hand.
The eligibility definitions. MRR for facility purposes is not MRR from the board deck. Month-to-month contracts, customers past due beyond a threshold, and concentration above a cap are commonly excluded. A churn event frequently moves two of those at once, so the measured decline exceeds the operational one.
What to do if the reset has already happened
The useful sequence is short. Produce the borrowing base yourself before the lender does, so the conversation starts with your numbers. Separate the permanent decline from the timing, because a customer that churned is different from one that is late. Bring the recovery plan and the cash to cover the gap in the same meeting rather than in two.
And treat it as a structuring problem rather than a credit problem, because that is usually what it is. The business did not become unfinanceable. One definition in a document produced a number that no longer matched it.
How Thalos Capital Approaches This
Thalos Capital works borrower-side on recurring revenue debt for United States technology companies, through two non-dilutive structures: an Amortized Term Facility for companies with $2 million to $20 million of ARR, and an Interest-Only Facility for companies with $5 million of ARR and above.
The work is to model the facility against a quarter that goes wrong, not only the plan. What the test measures, how often, over what period, what the cure looks like, and what happens to availability at the point the business is most likely to be drawn.
Then the same structure goes to more than one source, because lookback periods, floors and cure rights vary considerably, and those differences are worth more than a point of rate in exactly the quarter they matter.
The company in the example did not break a covenant or miss a payment. It grew into its facility, and then the facility shrank.
Most financing situations have more options than the borrower initially sees. A conversation is enough to map them. Submit your financing request at https://thaloscapital.com/contact.